Lessons from the First Clinical Trial to Reverse Cognitive Decline

Though the research pace for Alzheimer’s has been glacial, a monumental shift occurred: Our precision medicine protocol, which targets the root causes of cognitive decline, just produced the first clinical trial success for treating Alzheimer's and MCI.

Unlike other trials, which have only managed to slow disease progression slightly at best, 84% of participants in Dr. Bredesen’s trial experienced improvements in their cognition, with the average leaping from the 38th to 63rd percentile — a 65.7% improvement. There were also measurable improvements in brain volume and wellbeing assessments.

00:00 Introduction and Welcome
3:40 The State of Alzheimer's
11:07 Improving the System
13:51 Theories of Alzheimer's and Understanding the Disease
20:41 Precision Medicine Trial for Alzheimer's
22:51 Trial Results
26:20 Bredesen Seven
44:16 Ready to Get Started
45:44 For Practitioners and Coaches: ReCODE 2.0 Training
48:36 Q&A

Slides can be viewed here: https://mcusercontent.com/052574c3860df247d32a796de/files/154edf43-46f7-c00e-2031-1a92d63e62b3/Webinar_DB_8.3.22.pdf

Free Cq Assessment: http://www.mycqtest.com/
ReCODE 2.0 Training For Practitioners: https://www.apollohealthco.com/practitioners/
ReCODE 2.0 Training For Coaches: http://apollohealthcoaching.com/